Overall, while Lf-based NPs show considerable promise for enhancing drug delivery to glioma, particularly in the context of BBB disruption or tumor-induced permeability changes, their capacity for efficient transcytosis across an intact BBB appears limited, warranting further investigation. The gene discussed is LTF; the disease is glioma.